Pharma News

CytomX Therapeutics, Inc.  announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic for the treatment of cancer.  The company plans to immediately initiate the study and open clinical sites to support patient enrollment.

CytomX Therapeutics, Inc. announced that Bristol-Myers Squibb Company has selected a clinical candidate for its CTLA-4 Probody program under the strategic oncology collaboration established in May 2014.  Achieving this milestone results in a $2 million payment to CytomX.

BioDelivery Sciences International, Inc. (BDSI) announced that its phase 2b clinical study assessing the efficacy and safety of Clonidine topical gel for the management of painful diabetic neuropathy failed to show a statistically significant difference in pain relief between Clonidine topical gel and placebo.  As a result, BDSI is discontinuing further development of the product at this time.

The U.S. Food and Drug Administration  approved Maci (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. Maci is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. Maci is manufactured by Vericel Corporation, headquartered in Cambridge, Massachusetts.

Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, announced that it has received the final End of Phase II (EOP2) meeting minutes from the U.S. Food & Drug Administration Division of Pulmonary, Allergy and Rheumatology Products. The minutes are consistent with the preliminary responses that were issued to the Company prior to the meeting which took place on October 25, 2016.

Daiichi Sankyo Company, Limited  and DarwinHealth announced a strategic partnership to use quantitative systems biology-based algorithms and novel, validated approaches focused on tumour checkpoints - a new class of cancer targets - to help prioritize investigational compounds in the Daiichi Sankyo Cancer Enterprise pipeline for clinical development.

Alvogen, the next generation pharmaceuticals company, has launched the first generic equivalent to Tamiflu (oseltamivir phosphate) capsules in the United States.

CDSCO decided to abolish practice of pre-inspection by State Licensing Authority & Central Licensing Authority for issuing Form 29 License to manufacture drugs for purposes of examination, test or analysis for biological products (Vaccines & r-DNA products).

[adsense:336x280:8701650588]

Sun Pharmaceutical Industries Ltd and its subsidiaries and Israel-based Moebius Medical have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis.

[adsense:336x280:8701650588]